Gyre Therapeutics (NASDAQ:GYRE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a hold rating to a buy rating in a report published on Saturday morning.

A number of other equities research analysts have also commented on the stock. Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Wednesday, October 8th. Jefferies Financial Group initiated coverage on Gyre Therapeutics in a report on Friday, October 10th. They set a “buy” rating and a $16.00 price target for the company. Finally, HC Wainwright initiated coverage on Gyre Therapeutics in a research report on Tuesday, August 26th. They issued a “buy” rating and a $18.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

Shares of GYRE stock opened at $8.02 on Friday. The stock has a market capitalization of $772.59 million, a PE ratio of 802.80 and a beta of 1.88. The business’s 50 day simple moving average is $7.75 and its 200 day simple moving average is $8.07. Gyre Therapeutics has a one year low of $6.11 and a one year high of $14.42.

Institutional Investors Weigh In On Gyre Therapeutics

A number of large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gyre Therapeutics by 18.7% during the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock worth $127,000 after purchasing an additional 2,596 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Gyre Therapeutics in the 1st quarter valued at about $184,000. Advantage Alpha Capital Partners LP raised its stake in Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after buying an additional 4,790 shares during the period. Finally, SBI Securities Co. Ltd. boosted its holdings in Gyre Therapeutics by 87.9% in the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock worth $1,707,000 after acquiring an additional 108,670 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.